Free tool
FAERS Monitor: Lescol Xl
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021192 or its brand name (Lescol Xl, Fluvastatin Sodium). Reports on generic versions are filed under their own applications.
Reports
4,471
Serious
3,641
81% of reports
Hospitalization
1,949
Death reported
462
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea319
- myalgia317
- dizziness298
- fatigue280
- diarrhoea255
- drug ineffective253
- dyspnoea250
- asthenia243
- myocardial infarction221
- fall211
- vomiting207
- arthralgia201
- headache195
- cerebrovascular accident180
- pyrexia180
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 359 |
| 2005 | 422 |
| 2006 | 355 |
| 2007 | 238 |
| 2008 | 232 |
| 2009 | 257 |
| 2010 | 259 |
| 2011 | 351 |
| 2012 | 254 |
| 2013 | 165 |
| 2014 | 179 |
| 2015 | 192 |
| 2016 | 182 |
| 2017 | 145 |
| 2018 | 167 |
| 2019 | 126 |
| 2020 | 117 |
| 2021 | 132 |
| 2022 | 108 |
| 2023 | 64 |
| 2024 | 93 |
| 2025 | 40 |
| 2026 | 34 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,688 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myalgiaSignal | 317 | 8.8 | 7.9 | 2,193 |
| myocardial infarctionSignal | 221 | 6.0 | 5.2 | 915 |
| cerebrovascular accidentSignal | 180 | 5.0 | 4.3 | 576 |
| astheniaSignal | 243 | 3.0 | 2.7 | 337 |
| fallSignal | 211 | 3.0 | 2.6 | 281 |
| dizzinessSignal | 298 | 2.8 | 2.5 | 354 |
| pyrexiaSignal | 180 | 2.4 | 2.1 | 155 |
| arthralgiaSignal | 201 | 2.3 | 2.0 | 145 |
| dyspnoeaSignal | 250 | 2.1 | 1.8 | 143 |
| vomitingSignal | 207 | 2.1 | 1.8 | 116 |
| nausea | 319 | 1.9 | 1.7 | 139 |
| diarrhoea | 255 | 1.9 | 1.6 | 103 |
| fatigue | 280 | 1.7 | 1.5 | 82 |
| headache | 195 | 1.5 | 1.3 | 29 |
| drug ineffective | 253 | 0.9 | 0.8 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.